Mozobil Application Scope

Mozobil is a medication used to mobilize hematopoietic stem cells into the peripheral blood for collection and subsequent transplantation in patients with certain blood cancers, such as multiple myeloma.

Characteristics

Ingredients: Plerixafor

Properties:
- Clear, colorless to pale‑yellow sterile solution for subcutaneous injection
- Acts by antagonizing the CXCR4 receptor to release stem cells from the bone marrow
Packaging Specification: Single‑use glass vial; 1.2 mL at 20 mg/mL strength (24 mg total)

Storage: Store at 20–25 °C (68–77 °F); inspect vial for particulates or discoloration before use
Expiry Date: As labeled on vial—discard after the expiration date; unused portion should be discarded
Executive Standard: FDA NDA 022311; Canada SCN 280337
Approval Number: FDA NDA 022311; Supplemental sNDA 022311/S‑023 (June 15, 2023)
Date of Revision:
- FDA sNDA approved June 15, 2023;
- U.S. label revised September 2023;
- Canadian monograph revised Feb 15, 2024

Manufacturer: Sanofi‑Genzyme (Genzyme Corporation)

Guidelines for the Use of Mozobil

Dosage and Administration:
- Begin after 4 days of daily G‑CSF (10 µg/kg)
- Administer subcutaneously about 6–11 hours before apheresis, for up to 4 consecutive days (some studies up to 7 days)
- Dose by weight:
  - ≤ 83 kg: either fixed 20 mg or 0.24 mg/kg
  -  83 kg: 0.24 mg/kg (not to exceed 40 mg/day)
- Renal impairment (creatinine clearance ≤50 mL/min): reduce dose to 0.16 mg/kg (max 27 mg/day)

Adverse Reactions:
Common (≥ 10%):
- Digestive: diarrhea, nausea, vomiting
- General: fatigue, headache, arthralgia, dizziness, injection‑site reactions
Serious:
- Hypersensitivity/anaphylaxis, splenic enlargement/rupture
- Hematologic changes (leukocytosis, thrombocytopenia), mobilization of tumor cells
Contraindications:
- History of hypersensitivity to plerixafor (anaphylaxis reported)
- Not for patients with leukemia due to risk of mobilizing malignant cells
Precautions:
- Monitor blood counts, spleen size, signs of allergy
- Women of reproductive potential should use contraception
- Avoid during pregnancy and breastfeeding
- Male fertility considerations—use contraception during and one week after treatment

Mozobil Interactions

Drug Interactions: No significant interactions via cytochrome P450 system identified

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.